• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by scPharmaceuticals Inc.

    4/21/25 4:12:38 PM ET
    $SCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SCPH alert in real time by email
    DEFA14A 1 scph-defa14a-2025_v2.htm DEFA14A DEFA14A

    f

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A INFORMATION

    Proxy Statement Pursuant to Section 14(a) of
    the Securities Exchange Act of 1934 (Amendment No. )

     

    Filed by the Registrant 

     

    Filed by a Party other than the Registrant 

     

    Check the appropriate box:

     

     

     

    

    Preliminary Proxy Statement

     

     

     

    

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

     

     

    

    Definitive Proxy Statement

     

     

     

    

    Definitive Additional Materials

     

     

     

    

    Soliciting Material under §240.14a-12

     

    SCPHARMACEUTICALS INC.

    (Name of Registrant as Specified In Its Charter)

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check all boxes that apply):

     

     

     

    

    No fee required.

     

     

     

    

    Fee paid previously with preliminary materials.

     

     

     

    

    Fee computed on table in exhibit required by Item 25 (b) per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

     

     

     

     

     


     

    img62454858_0.jpgYour Vote Counts! SCPHARMACEUTICALS INC. 2025 Annual Meeting Vote by June 2, 2025 11:59 PM ET SCPHARMACEUTICALS INC. 25 MALL RD., SUITE 203 BURLINGTON, MA 01803 V68554-P26610 You invested in SCPHARMACEUTICALS INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on June 3, 2025. Get informed before you vote View the Notice and Proxy Statement and 2024 Annual Report on Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 20, 2025. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. For complete information and to vote, visit www.ProxyVote.com Control # Smartphone users Point your camera here and vote without entering a control number Vote Virtually at the Meeting* June 3, 2025 12:30 PM Eastern Time Virtually at: www.virtualshareholdermeeting.com/SCPH2025 *Please check the meeting materials for any special requirements for meeting attendance.
     

     


     

    img62454858_1.jpg Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote on these important matters. Board Recommends Voting Items 1. Election of Class II Directors For Nominees: 01) William T. Abraham, M.D. 02) Mette Kirstine Agger 03) Minnie Baylor-Henry 2. To ratify the appointment of RSM US LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025. For 3. To approve, on an advisory (non-binding) basis, the compensation of the Company’s named executive officers. For NOTE: The Board of Directors will consider and act upon any other business as may properly come before the annual meeting or any continuation, adjournment or postponement thereof. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. V68555-P26610

     


    Get the next $SCPH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SCPH

    DatePrice TargetRatingAnalyst
    9/7/2023$20.00Buy
    Craig Hallum
    12/1/2022$25.00Outperform
    Cowen
    10/21/2022$14.00Buy
    Jefferies
    10/11/2022$11.00Mkt Perform → Outperform
    SVB Leerink
    8/2/2022$10.00Buy
    Maxim Group
    9/9/2021$6.00Market Perform
    SVB Leerink
    More analyst ratings

    $SCPH
    Financials

    Live finance-specific insights

    See more
    • scPharmaceuticals to Announce First Quarter 2025 Financial Results After the Market Close on May 14, 2025

      BURLINGTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, May 14, 2025, to discuss the financial results for the first quarter 2025 and provide a business update. Registration and access for the conference call can be completed through this direct registration link. The live webcast and replay of the conference call can be accessed here or under "News & Events" in the Investor Relations section of the Company's website,

      5/7/25 4:01:44 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      scPharmaceuticals generated fourth quarter 2024 net FUROSCIX® revenue of $12.2 million, and full year 2024 revenue of $36.3 million Cash and cash equivalents of $75.7 million as of December 31, 2024 U.S. Food and Drug Administration (FDA) approved the FUROSCIX expanded label indication to include the treatment of edema due to fluid overload in patients with chronic kidney disease scPharmaceuticals to host investor conference call and webcast today, Wednesday, March 19th, at 4:30pm ET BURLINGTON, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH) (the "Company"), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through pat

      3/19/25 4:01:00 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, March 19, 2025

      BURLINGTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, March 19, 2025, to discuss the financial results for the fourth quarter and full year 2024, and provide a business update. Registration and access for the conference call can be completed through this direct registration link. The live webcast and replay of the conference call can be accessed here or under "News & Events" in the Investor Relations section of the

      3/12/25 4:01:00 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCPH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • scPharmaceuticals to Announce First Quarter 2025 Financial Results After the Market Close on May 14, 2025

      BURLINGTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, May 14, 2025, to discuss the financial results for the first quarter 2025 and provide a business update. Registration and access for the conference call can be completed through this direct registration link. The live webcast and replay of the conference call can be accessed here or under "News & Events" in the Investor Relations section of the Company's website,

      5/7/25 4:01:44 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • scPharmaceuticals Announces Participation in Three Upcoming Investor Conferences

      BURLINGTON, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH) (the "Company"), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that John Tucker, President and Chief Executive Officer, will participate in the following upcoming investor conferences: The Citizens Life Sciences Conference: Presentation on Wednesday, May 7 at 9:30 a.m. ET.Craig-Hallum 22nd Annual Institutional Investor Conference: Wednesday, May 28, Investor Meetings OnlyH.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ: Presentation on May 20 at 10:00 a.m. ET. A webcast of the presentations

      5/1/25 4:01:00 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      scPharmaceuticals generated fourth quarter 2024 net FUROSCIX® revenue of $12.2 million, and full year 2024 revenue of $36.3 million Cash and cash equivalents of $75.7 million as of December 31, 2024 U.S. Food and Drug Administration (FDA) approved the FUROSCIX expanded label indication to include the treatment of edema due to fluid overload in patients with chronic kidney disease scPharmaceuticals to host investor conference call and webcast today, Wednesday, March 19th, at 4:30pm ET BURLINGTON, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH) (the "Company"), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through pat

      3/19/25 4:01:00 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCPH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for FUROSCIX issued to SCPHARMACEUTICALS INC

      Submission status for SCPHARMACEUTICALS INC's drug FUROSCIX (ORIG-1) with active ingredient FUROSEMIDE has changed to 'Approval' on 10/07/2022. Application Category: NDA, Application Number: 209988, Application Classification: Type 3 - New Dosage Form

      10/11/22 1:54:57 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCPH
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by scPharmaceuticals Inc.

      SCHEDULE 13G/A - scPharmaceuticals Inc. (0001604950) (Subject)

      4/28/25 4:01:03 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by scPharmaceuticals Inc.

      DEFA14A - scPharmaceuticals Inc. (0001604950) (Filer)

      4/21/25 4:12:38 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by scPharmaceuticals Inc.

      DEF 14A - scPharmaceuticals Inc. (0001604950) (Filer)

      4/21/25 4:10:57 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on scPharmaceuticals with a new price target

      Craig Hallum initiated coverage of scPharmaceuticals with a rating of Buy and set a new price target of $20.00

      9/7/23 9:06:27 AM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cowen initiated coverage on scPharmaceuticals with a new price target

      Cowen initiated coverage of scPharmaceuticals with a rating of Outperform and set a new price target of $25.00

      12/1/22 7:54:00 AM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies resumed coverage on scPharmaceuticals with a new price target

      Jefferies resumed coverage of scPharmaceuticals with a rating of Buy and set a new price target of $14.00

      10/21/22 7:40:23 AM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCPH
    Leadership Updates

    Live Leadership Updates

    See more
    • Lantheus Announces Appointment of Minnie Baylor-Henry as New Board Member

      NORTH BILLERICA, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("the Company") (NASDAQ:LNTH), today announced the appointment of Ms. Minnie Baylor-Henry, Esq., a renowned expert in regulatory affairs and compliance in the life sciences industry, to Lantheus' Board of Directors ("Board"), effective immediately. As an independent director, Ms. Baylor-Henry will serve as a member of the Board's Compensation Committee and the Science and Technology Committee. Following the appointment of Ms. Baylor-Henry, the Board will be comprised of nine directors, eight of whom are independent. "We are pleased to welcome Minnie Baylor-Henry, a highly respected authority in FDA law an

      3/1/22 4:05:00 PM ET
      $APYX
      $LNTH
      $PRTK
      $SCPH
      Medical/Dental Instruments
      Health Care
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Biotechnology: Pharmaceutical Preparations

    $SCPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Tucker John H gave a grant of 200,000 shares, decreasing direct ownership by 31% to 440,847 units (SEC Form 4)

      4 - scPharmaceuticals Inc. (0001604950) (Issuer)

      2/12/25 4:32:59 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CFO and Treasurer Nokes Rachael was granted 88,445 shares, increasing direct ownership by 131% to 156,061 units (SEC Form 4)

      4 - scPharmaceuticals Inc. (0001604950) (Issuer)

      2/12/25 4:27:03 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CFO and Treasurer Nokes Rachael covered exercise/tax liability with 5,235 shares, decreasing direct ownership by 7% to 67,616 units (SEC Form 4)

      4 - scPharmaceuticals Inc. (0001604950) (Issuer)

      1/7/25 4:30:06 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCPH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Orbimed Advisors Llc bought $2,000,000 worth of shares (500,000 units at $4.00) (SEC Form 4)

      4 - scPharmaceuticals Inc. (0001604950) (Issuer)

      8/15/24 4:51:14 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by scPharmaceuticals Inc.

      SC 13G/A - scPharmaceuticals Inc. (0001604950) (Subject)

      11/15/24 4:06:50 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by scPharmaceuticals Inc.

      SC 13G/A - scPharmaceuticals Inc. (0001604950) (Subject)

      11/14/24 5:48:35 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by scPharmaceuticals Inc.

      SC 13G/A - scPharmaceuticals Inc. (0001604950) (Subject)

      11/14/24 3:58:44 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care